Table 1. Characteristics of study sample for GWAS.
| Patient demographics | |
| Self-reported gender, % female | 79.5 |
| Age, mean (S.D) years | 56+/-12 |
| Duration, years | |
| Mean (S.D.) | 9.1+/-9.0 |
| Median (interquartile range) | 6.0 (2.3–13.6) |
| Disease duration <2 years, n (%) | 66 (21.8) |
| Tender joint count, mean (S.D.) | 15.4+/-6.8 |
| DAS 28 (ESR), mean (S.D.) | 6.4+/-1.0 |
| ACR20 at week 6, n (%) | 138 (45.7) |
| ACR20 at week 12, n (%) | 146 (48.3) |
| ACR70 at week 6, n (%) | 17 (5.6) |
| ACR70 at week 12, n (%) | 34 (11.3) |
| Self-reported ethnicity, n (%) | |
| Caucasian | 293 (97.0) |
| CRP, mg/l; Median (interquartile range) | 9.0 (5.0–18.0) |
| ESR, mm/h: Median (interquartile range) | 36.0 (25.0–51.0) |
| Anti-CCP positive at baseline, n (%) | 180 (66.4) |
| RF positive at baseline, n (%) | 208 (74.8) |
| Treatment history | |
| Previous TNF inhibitor use, n (%) | 142 (47.0) |
| Other Medication at baseline, n (%) | |
| Methotrexate | 216 (71.5) |
| Steroids | 186 (61.6) |
| Statins | 68 (22.5) |
| Lefluonamide | 21 (7.0) |
| Azathioprine | 1 (0.03) |
ACR20, 20% improvement in ACR score; ACR70, 70% improvement in ACR score; DAS, Disease Activity Score; CCP, cyclic citrullinated peptide; RF, rheumatoid factor.